WO1995006470A1 - Prevention and treatment of alzheimer's disease - Google Patents
Prevention and treatment of alzheimer's disease Download PDFInfo
- Publication number
- WO1995006470A1 WO1995006470A1 PCT/US1994/007518 US9407518W WO9506470A1 WO 1995006470 A1 WO1995006470 A1 WO 1995006470A1 US 9407518 W US9407518 W US 9407518W WO 9506470 A1 WO9506470 A1 WO 9506470A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hmg
- coa reductase
- reductase inhibitor
- alkyl
- patient
- Prior art date
Links
- MQKYSYNFKMBLDQ-QEBFGESMSA-N C/C=C/C(/c1nnn[n]1C)=C/c1ccc(C)cc1-c(cc1)ccc1F Chemical compound C/C=C/C(/c1nnn[n]1C)=C/c1ccc(C)cc1-c(cc1)ccc1F MQKYSYNFKMBLDQ-QEBFGESMSA-N 0.000 description 1
- KKZQBMBBMJKIRQ-BRJRFNKRSA-N CC(C[C@H](C1)O)OC1=O Chemical compound CC(C[C@H](C1)O)OC1=O KKZQBMBBMJKIRQ-BRJRFNKRSA-N 0.000 description 1
- 0 CCCC(C1C(C*(*)C2)OC(I)=O)[C@@](C)CCC12C=C Chemical compound CCCC(C1C(C*(*)C2)OC(I)=O)[C@@](C)CCC12C=C 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
Definitions
- the present invention relates to the administration of an HMG-CoA reductase inhibitor, including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to humans to lower ApoUpoprotein E isoform 4 (ApoE isoform 4) levels in the central nervous system to treat, arrest the development of and prevent the onset of Alzheimer's disease.
- HMG-CoA reductase inhibitor including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to humans to lower ApoUpoprotein
- Alzheimer's disease is a neurodegenerative disease of the brain leading to severely impaired cognition and functionality. This disease leads to progressive regression of memory and learned functions. Alzheimer's disease is a complex disease that affects cholinergic neurons, as well as serotonergic, noradrenergic and other central neurotransmitter systems. Manifestations of Alzheimer's disease extend beyond memory loss and include personality changes, neuromuscular changes, seizures, and occasionally psychotic features.
- Alzheimer's disease is the most common type of dementia in the United States. Some estimates suggest that up to 47% of those older than 85 years have Alzheimer's disease. Since the average age of the population is on the increase, the frequency of Alzheimer's disease is increasing and requires urgent attention. Alzheimer's is a difficult medical problem because there are presently no adequate methods available for its prevention or treatment.
- the first class consists of compounds that augment acetylcholine neurotransmitter function.
- cholinergic agonists such as the antichohnesterase drugs are being used in the treatment of Alzheimer's disease.
- physostigmine eserine
- the administration of physostigmine has the drawback of being considerably limited by its short half-life of effect, poor oral bioavailabihty, and severe dose-limiting side-effects, particularly towards the digestive system.
- Tacrine tetrahydroaminocridine
- this compound may cause hepatotoxicity.
- a second class of drugs that are being investigated for the treatment of Alzheimer's disease is neurotropics that affect neuron metabolism with little effect elsewhere. These drugs improve nerve cell function by increasing neuron metabolic activity.
- Piracetam is a neurotropic that may be useful in combination with acetylcholine precursors and may benefit Alzheimer's patients who retain some quantity of functional acetylcholine neurons.
- Oxiracetam is another related drug that has been investigated for Alzheimer treatment.
- a third class of drugs include those drugs that affect brain vasculature.
- a mixture of ergoloid mesylates is used for the treatment of dementia. Ergoloid mesylates decrease vascular resistance and thereby increase cerebral blood flow.
- calcium channel blocking drugs including Nimodipine which is a selective calcium channel blocker that affects primarily brain vasculature.
- miscellaneous drugs are targeted to modify other defects found in Alzheimer's disease.
- Selegiline a monoamine oxidase B inhibitor which increases brain dopamine and norepinephrine has reportedly caused mild improvement in some Alzheimer's patients.
- Aluminum chelating agents have been of interest to those who believe Alzheimer's disease is due to aluminum toxicity.
- Drugs that affect behavior including neuroleptics, and anxiolytics have been employed. Side effects of neuroleptics range from drowsiness and anti cholinergic effects to extrapyramidal side effects; other side effects of these drugs include seizures, inappropriate secretion of antidiuretic hormone, jaundice, weight gain and increased confusion.
- Anxiolytics which are mild tranquilizers, are less effective than neuroleptics, but also have milder side effects. Use of these behavior-affecting drugs, however, remains controversial.
- Apolipoprotein E type 4 allele was more than eight times as likely to be affected with Alzheimer's disease than individuals who did not possess any copies of the Apolipoprotein E type 4 allele.
- the protein encoded by Apolipoprotein E type 4 allele, ApoE isoform 4 has a higher avidity in vitro for ⁇ -amyloid than ApoE isoform 3.
- Apolipoprotein E is the major apolipoprotein in the central nervous system, where it appears to be involved in nerve regeneration following injury. Apolipoprotein E is synthesized in several extra hepatic tissues, including brain, and is catabolized predominantly by the liver.
- the present invention provides for a method of treating, arresting the development of and preventing Alzheimer's disease by regulating the amount of ApoE isoform 4 circulating in the bloodstream and in the brain, most particularly in the brain of a patient with or at risk of developing Alzheimer's disease employing an HMG-CoA reductase inhibitor selected from lovastatin and simvastatin, including the corresponding open-ring dihydroxy acid forms and the salts and esters thereof.
- an HMG-CoA reductase inhibitor selected from lovastatin and simvastatin, including the corresponding open-ring dihydroxy acid forms and the salts and esters thereof.
- Lovastatin (MEVACOR®), simvastatin (ZOCOR®) pravastatin (PRAVACHOL®), and fluvastatin (LESCOL®) are known cholesterol lowering agents.
- These compounds are inhibitors of HMG-CoA reductase, which is the rate-limiting step in the biosynthesis of cholesterol.
- Lovastatin and related compounds are disclosed in U.S. Patent No. 4,231 ,938; simvastatin and related comounds are disclosed in U.S. Patent No. 4,450,171 and U.S. Patent No. 4,346,227; pravastatin and related compounds are disclosed in U.S. Patent No. 4,346,227 and fluvastatin and related compounds such as disclosed in PCT Publication WO 84/02131.
- the present invention provides for a method of preventing and treating Alzheimer's disease by treating a patient in need of such treatment with an HMG-CoA reductase inhibitor, including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to lower Apolipoprotein E isoform 4 (ApoE isoform 4) levels in the central nervous system.
- an HMG-CoA reductase inhibitor including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to lower Apolipoprotein E
- the present invention relates to administration of an HMG- CoA reductase inhibitor to humans at risk for developing Alzheimer's disease for the purpose of preventing the onset of Alzheimer's disease.
- the HMG-Co A reductase inhibitors which are used in the method of this invention include the compounds represented by the following structural formula (I):
- Z is selected from:
- R2 is selected from:
- Ci-3 alkyl substituted with hydroxy; R3 is selected from:
- X is NCH(CH 3 ) 2 or C(CH 2 ) 4 .
- R4 and R ⁇ are each independently selected from hydrogen, halogen, Ci-4 alkyl, Ci-4 alkoxy and trifluoromethyl, and
- R5, R6, R7 5 and R8 are each independently selected from hydrogen, halogen, C ⁇ _4 alkyl, and Cl-4 alkoxy; the corresponding open-ring dihydroxy acid forms thereof and pharmaceutically acceptable salts and esters thereof.
- open-ring dihydroxy acid form and pharmaceutically acceptable salts and esters of the compound of formula (I) refers to the corresponding compound of formula (II) below:
- RlO is selected from:
- the pharmaceutically acceptable salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethyl ammonium hydroxide.
- bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)amin
- One class of compounds of the present invention are those wherein Z is:
- R3 is 5-OH, and a, b, c, and d are each single bonds.
- Another subclass of compounds is characterized by R3 being 3-oxo and a and c being a double bond, or c being a double bond.
- R3 is 7-(l-hydroxyethyl), b and d are double bonds; provided that when R2 is OH, b and d are double bonds or c is a double bond or a, b, c, and d are single bonds.
- Another class of compounds of the present invention are those wherein Z is:
- preventing includes not only preventing of the onset of the disease in disease-free patients, but also arresting the development of the disease in patients already manifesting symptoms of the disease, and ameliorating symptoms in patients afflicted with the disease.
- the method of this invention is useful for treating individuals who possess one or two copies of the apolipoprotein E type 4 allele. These individuals are more likely to develop late onset and sporadic Alzheimer's disease.
- the method of this invention is also useful in halting the progression of Alzheimer's disease in a patient who already exhibits symptoms of dementia, and ameliorating the degenerative effects of Alzheimer's disease.
- the present invention provides for a means of lowering the levels of Apolipoprotein E isoform 4 circulating in the bloodstream and in the brain by employing an HMG-CoA reductase inhibitor of structural formula (I) the open ring dihydroxy acid forms thereof and salts and esters thereof.
- this invention relates to the lowering of Apolipoprotein E isoform 4 circulating through the central nervous system and present in the cerebrospinal fluid.
- Apolipoprotein E isoform 4 (“ApoE isoform 4”) is an apolipoprotein which is the gene product of the apolipoprotein E type 4 allele. Possession of one or two copies of the apolipoprotein E type 4 allele has been linked to a greatly increased risk of developing Alzheimer's disease.
- the present invention provides for a method of decreasing circulating blood levels of ApoE isoform 4 throughout the body, including the brain. In the liver, low density lipoprotein receptors (LDL receptors) are responsible for absorbing and taking up from the bloodstream various lipoproteins including some of those containing ApoE isoform 4. LDL receptors are regulated by gene repressors derived from cholesterol which suppress the transcription of the LDL-receptor.
- LDL receptors are regulated by gene repressors derived from cholesterol which suppress the transcription of the LDL-receptor.
- Inhibition of cholesterol biosynthesis reduces the presence of these cholesterol-derived LDL gene repressors. This relieves the suppression of the production of the LDL receptor, leading to production of additional LDL receptors in the liver, which, in turn, remove additional ApoE containing lipoproteins from the bloodstream.
- Reduced levels of ApoE isoform 4 in the bloodstream promotes an increase in the flux of ApoE isoform 4 from the CNS to the plasma, thus reducing the risk of, halting the development of and/or ameliorating the symptoms of Alzheimer's disease. It is also possible that these agents could work directly on the CNS to reduce ApoE levels in the brain.
- the HMG-CoA reductase inhibitor of structural formula (I), the open-ring dihydroxy acid forms thereof, and salts and esters thereof may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers. It is usually desirable to use the oral route.
- the compounds of structural formula (I), the open-ring dihydroxy acid forms thereof, and salts and esters thereof may be administered orally in the form of a capsule, a tablet or the like.
- the orally administered medicament may be administered in the form of a time-controlled release vehicle, including diffusion controlled systems, osmotic devices, dissolution controlled matrices and erodible/degradable matrices.
- Doses may be varied, depending on the age, severity, body weight and other conditions of human patients, but daily dosage for adults is within a range of from about 1 mg to 1000 mg (preferably 5 to 100 mg,) which may be given in a single dose or in two to four divided doses. Higher doses may be favorably employed as required.
- HF high fat
- LF low fat
- P placebo
- L lovastatin
- ApoE unit is mg/dl.
- HMG-CoA reductase inhibitors The following protocol is used to determine the effect of HMG-CoA reductase inhibitors on cerebrospinal fluid levels of ApoE in Alzheimer's patients homozygous for ApoE type 4 allele.
- Other HMG- CoA reductase inhibitors may be substituted for simvastatin.
- a randomized, double-blind placebo controlled, parallel- design, multicenter six week study is conducted. Approximately 30 men and women (to provide 20 patients with baseline and follow-up lumbar punctures) between the ages of 50 and 85 years with a diagnosis of sporadic or late-onset familial AD, homozygous for the ApoE4 isoform, and with a low density lipoprotein (LDL) cholesterol level greater than 100 mg/dl are recruited for participation in the study and informed consent is obtained. (Patients incapable of giving informed consent have written consent from their guardian or representative.)
- LDL low density lipoprotein
- Patients qualifying for entry after screening are randomized to simvastatin, 40 mg/day or placebo for six weeks.
- a lumbar puncture will be performed prior to randomization and at Week 6 to determine cerebrospinal fluid levels of ApoE and other apolipoproteins. If the lumber puncture is judged traumatic (greater than grossly hemorrhage and greater than 50,000 RBC/mm ⁇ F), it is repeated in one week. Plasma is obtained at these time points for plasma total, LDL, HDL cholesterol and apolipoproteins including ApoE. For those patients in whom the six week lumbar puncture follow-up cannot be performed on time, a two week window is allowed (Week 4 to 8 of active treatment).
- the primary endpoint is a comparison between simvastatin and placebo groups in the mean cerebrospinal ApoE levels.
Abstract
The present invention relates to the administration of an HMG-CoA reductase inhibitor, including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to humans to lower Apolipoprotein E isoform 4 (ApoE isoform 4) levels in the central nervous system to treat, arrest the development of and prevent the onset of Alzheimer's disease.
Description
TITLE OF THE INVENTION
PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
SUMMARY OF THE INVENTION
The present invention relates to the administration of an HMG-CoA reductase inhibitor, including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to humans to lower ApoUpoprotein E isoform 4 (ApoE isoform 4) levels in the central nervous system to treat, arrest the development of and prevent the onset of Alzheimer's disease.
BACKGROUND OF THE INVENTION
Alzheimer's disease is a neurodegenerative disease of the brain leading to severely impaired cognition and functionality. This disease leads to progressive regression of memory and learned functions. Alzheimer's disease is a complex disease that affects cholinergic neurons, as well as serotonergic, noradrenergic and other central neurotransmitter systems. Manifestations of Alzheimer's disease extend beyond memory loss and include personality changes, neuromuscular changes, seizures, and occasionally psychotic features.
Alzheimer's disease is the most common type of dementia in the United States. Some estimates suggest that up to 47% of those older than 85 years have Alzheimer's disease. Since the average age of the population is on the increase, the frequency of Alzheimer's disease is increasing and requires urgent attention. Alzheimer's is a difficult medical problem because there are presently no adequate methods available for its prevention or treatment.
Three classes of drugs are being investigated for the treatment of Alzheimer's disease. The first class consists of compounds that augment acetylcholine neurotransmitter function. Currently, cholinergic agonists such as the antichohnesterase drugs are being used in the treatment of Alzheimer's disease. In particular, physostigmine
(eserine), an inhibitor of acetylcholinesterase, has been used in its treatment. The administration of physostigmine has the drawback of being considerably limited by its short half-life of effect, poor oral bioavailabihty, and severe dose-limiting side-effects, particularly towards the digestive system. Tacrine (tetrahydroaminocridine) is another cholinesterase inhibitor that has been employed; however, this compound may cause hepatotoxicity.
A second class of drugs that are being investigated for the treatment of Alzheimer's disease is neurotropics that affect neuron metabolism with little effect elsewhere. These drugs improve nerve cell function by increasing neuron metabolic activity. Piracetam is a neurotropic that may be useful in combination with acetylcholine precursors and may benefit Alzheimer's patients who retain some quantity of functional acetylcholine neurons. Oxiracetam is another related drug that has been investigated for Alzheimer treatment.
A third class of drugs include those drugs that affect brain vasculature. A mixture of ergoloid mesylates is used for the treatment of dementia. Ergoloid mesylates decrease vascular resistance and thereby increase cerebral blood flow. Also employed are calcium channel blocking drugs including Nimodipine which is a selective calcium channel blocker that affects primarily brain vasculature.
Other miscellaneous drugs are targeted to modify other defects found in Alzheimer's disease. Selegiline, a monoamine oxidase B inhibitor which increases brain dopamine and norepinephrine has reportedly caused mild improvement in some Alzheimer's patients. Aluminum chelating agents have been of interest to those who believe Alzheimer's disease is due to aluminum toxicity. Drugs that affect behavior, including neuroleptics, and anxiolytics have been employed. Side effects of neuroleptics range from drowsiness and anti cholinergic effects to extrapyramidal side effects; other side effects of these drugs include seizures, inappropriate secretion of antidiuretic hormone, jaundice, weight gain and increased confusion. Anxiolytics, which are mild tranquilizers, are less effective than neuroleptics, but also have
milder side effects. Use of these behavior-affecting drugs, however, remains controversial.
None of the drugs discussed above are targeted to prevent the onset of Alzheimer's disease. These drugs are employed as treatments for the disease. At best one or more of these drugs may slow down the course of the disease, but there is currently no evidence for this.
Recently, it has been reported in Corder et al.., "Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families," Science 261:921-23 (13 August 1993), that the Apolipoprotein E type 4 allele ("APOE-ε4") is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease. Specifically, it was found that the risk of Alzheimer's disease increased by a factor of 2.84 for each additional Apolipoprotein E type 4 allele the patient had. Hence, individuals with two copies of the Apoliprotein E type 4 allele were more than eight times as likely to be affected with Alzheimer's disease than individuals who did not possess any copies of the Apolipoprotein E type 4 allele. The protein encoded by Apolipoprotein E type 4 allele, ApoE isoform 4, has a higher avidity in vitro for β-amyloid than ApoE isoform 3. Apolipoprotein E is the major apolipoprotein in the central nervous system, where it appears to be involved in nerve regeneration following injury. Apolipoprotein E is synthesized in several extra hepatic tissues, including brain, and is catabolized predominantly by the liver.
The present invention provides for a method of treating, arresting the development of and preventing Alzheimer's disease by regulating the amount of ApoE isoform 4 circulating in the bloodstream and in the brain, most particularly in the brain of a patient with or at risk of developing Alzheimer's disease employing an HMG-CoA reductase inhibitor selected from lovastatin and simvastatin, including the corresponding open-ring dihydroxy acid forms and the salts and esters thereof.
Lovastatin (MEVACOR®), simvastatin (ZOCOR®) pravastatin (PRAVACHOL®), and fluvastatin (LESCOL®) are known cholesterol lowering agents.
PRAVASTATIN FLUVASTATIN
These compounds are inhibitors of HMG-CoA reductase, which is the rate-limiting step in the biosynthesis of cholesterol.
Lovastatin and related compounds are disclosed in U.S. Patent No. 4,231 ,938; simvastatin and related comounds are disclosed in U.S. Patent No. 4,450,171 and U.S. Patent No. 4,346,227; pravastatin and related compounds are disclosed in U.S. Patent No. 4,346,227 and fluvastatin and related compounds such as disclosed in PCT Publication WO 84/02131.
The present invention provides for a method of preventing and treating Alzheimer's disease by treating a patient in need of such
treatment with an HMG-CoA reductase inhibitor, including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to lower Apolipoprotein E isoform 4 (ApoE isoform 4) levels in the central nervous system.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to administration of an HMG- CoA reductase inhibitor to humans at risk for developing Alzheimer's disease for the purpose of preventing the onset of Alzheimer's disease. The HMG-Co A reductase inhibitors which are used in the method of this invention include the compounds represented by the following structural formula (I):
(I) wherein:
Z is selected from:
R*is Cl-10alkyl,
R2 is selected from:
(a) hydrogen,
(b) Ci-3 alkyl,
(c) hydroxy, and
(d) Ci-3 alkyl substituted with hydroxy; R3 is selected from:
(a) Cl-3 alkyl,
(b) hydroxy,
(c) oxo, and
(d) Cl-3 alkyl substituted with hydroxy; n is 0,1, or 2; a, b, c and d are all single bonds or a and c are double bonds or b and d are double bonds or one of a, b, c or d is a double bond;
wherein X is NCH(CH3)2 or C(CH2)4.
wherein R4 and R^ are each independently selected from hydrogen, halogen, Ci-4 alkyl, Ci-4 alkoxy and trifluoromethyl, and
R5, R6, R75 and R8 are each independently selected from hydrogen, halogen, Cι_4 alkyl, and Cl-4 alkoxy; the corresponding open-ring dihydroxy acid forms thereof and pharmaceutically acceptable salts and esters thereof.
The terms "halo" and "halogen" each refer to -F, -CI, -Br and
The term "open-ring dihydroxy acid form and pharmaceutically acceptable salts and esters" of the compound of formula (I) refers to the corresponding compound of formula (II) below:
(ii) wherein RlO is selected from:
(a) hydrogen,
(b) Cι_5alkyl,
(c) substituted C 1-5 alkyl in which the substituent is selected from the group consisting of:
(1) phenyl,
(2) dimethylamino, and
(3) acetylamino, and
(d) 2,3-dihydroxypropyl; and pharmaceutically acceptable salts thereof.
The pharmaceutically acceptable salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethyl ammonium hydroxide. These salts are prepared by standard procedures.
One class of compounds of the present invention are those wherein Z is:
and n is 1. One subclass of these compounds is where R3 is 5-OH, and a, b, c, and d are each single bonds. Another subclass of compounds is characterized by R3 being 3-oxo and a and c being a double bond, or c being a double bond. Yet a third subclass of these compounds is where R3 is 7-(l-hydroxyethyl), b and d are double bonds; provided that when R2 is OH, b and d are double bonds or c is a double bond or a, b, c, and d are single bonds.
Another class of compounds of the present invention are those wherein Z is:
As used herein the term "preventing" includes not only preventing of the onset of the disease in disease-free patients, but also arresting the development of the disease in patients already manifesting symptoms of the disease, and ameliorating symptoms in patients afflicted with the disease.
Specifically, the method of this invention is useful for treating individuals who possess one or two copies of the apolipoprotein E type 4 allele. These individuals are more likely to develop late onset and sporadic Alzheimer's disease. The method of this invention is also
useful in halting the progression of Alzheimer's disease in a patient who already exhibits symptoms of dementia, and ameliorating the degenerative effects of Alzheimer's disease.
The present invention provides for a means of lowering the levels of Apolipoprotein E isoform 4 circulating in the bloodstream and in the brain by employing an HMG-CoA reductase inhibitor of structural formula (I) the open ring dihydroxy acid forms thereof and salts and esters thereof. Particularly, this invention relates to the lowering of Apolipoprotein E isoform 4 circulating through the central nervous system and present in the cerebrospinal fluid.
Apolipoprotein E isoform 4 ("ApoE isoform 4") is an apolipoprotein which is the gene product of the apolipoprotein E type 4 allele. Possession of one or two copies of the apolipoprotein E type 4 allele has been linked to a greatly increased risk of developing Alzheimer's disease. The present invention provides for a method of decreasing circulating blood levels of ApoE isoform 4 throughout the body, including the brain. In the liver, low density lipoprotein receptors (LDL receptors) are responsible for absorbing and taking up from the bloodstream various lipoproteins including some of those containing ApoE isoform 4. LDL receptors are regulated by gene repressors derived from cholesterol which suppress the transcription of the LDL-receptor. Inhibition of cholesterol biosynthesis reduces the presence of these cholesterol-derived LDL gene repressors. This relieves the suppression of the production of the LDL receptor, leading to production of additional LDL receptors in the liver, which, in turn, remove additional ApoE containing lipoproteins from the bloodstream. Reduced levels of ApoE isoform 4 in the bloodstream promotes an increase in the flux of ApoE isoform 4 from the CNS to the plasma, thus reducing the risk of, halting the development of and/or ameliorating the symptoms of Alzheimer's disease. It is also possible that these agents could work directly on the CNS to reduce ApoE levels in the brain.
For the prevention, treatment or amelioration of the symptoms of Alzheimer's disease, the HMG-CoA reductase inhibitor of structural formula (I), the open-ring dihydroxy acid forms thereof, and
salts and esters thereof, may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers. It is usually desirable to use the oral route. The compounds of structural formula (I), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, may be administered orally in the form of a capsule, a tablet or the like. The orally administered medicament may be administered in the form of a time-controlled release vehicle, including diffusion controlled systems, osmotic devices, dissolution controlled matrices and erodible/degradable matrices. Doses may be varied, depending on the age, severity, body weight and other conditions of human patients, but daily dosage for adults is within a range of from about 1 mg to 1000 mg (preferably 5 to 100 mg,) which may be given in a single dose or in two to four divided doses. Higher doses may be favorably employed as required.
The following example is given for the purpose of illustrating the present invention and shall not be construed as being limitations on the scope or spirit of the invention.
EXAMPLE 1
Apolipoprotein E Polymorphism On ApoE Response To an HMG-CoA
Reductase Inhibitor
Method: One hundred eleven outpatients with moderate hypercholesterolemia were treated at five lipid clinics with the National Cholesterol Education Program Step 2 diet (which is low in fat and cholesterol) and lovastatin (20 mg once a day), both alone and together. A diet high in fat and cholesterol and a placebo identical n appearance to the lovastatin were used as the respective controls. Each of the 97 patients completing the study (58 men and 39 women) underwent four consecutive nine- week periods of treatment according to a randomized, balanced design: a high fat diet-placebo period, a low-fat diet— placebo period, a high-fat diet— lovastatin period, and a low-fat diet— lovastatin period.
Mean ApoE levels at the End of Each Intervention
Apo E HF/P LF/P HF/L LF/L p(dief) p(drug pheno- tvpe (n
3/3(52) 7.5 7.4 6.9 6.5 0.07 <0.001
3/4(26) 6.9 6.2 5.4 5.4 0.17 <0.001
4/4(5) 8.9 8.0 4.0 5.8 n too n too small small
HF=high fat; LF= low fat; P=placebo; L=lovastatin; ApoE unit is mg/dl. There is considerable variation of ApoE within and between patients. (This is true of other components of VLDL, including VLDL cholesterol and triglycerides.) Also, the sample sizes for the 4/4 and 3/4 phenotypes are relatively small. For these reasons, % change in the mean, (rather than mean or median % change is shown below:
% Change in Mean ApoE
phenotvpe (ή) due to diet due to drug
3/3 (52 -5 -1 1
3/4 (26) -7 -21
4/4 +7 -42
These data suggest that the serum level of ApoE isoform 4 falls more during treatment with lovastatin, an HMG-CoA reductase inhibitor, than does the level of ApoE isoform 3.
EXAMPLE 2
Effect of HMG-CoA Reductase Inhibitor on Cerebrospinal
Fluid Levels of ApoE in Alzheimer's Patients Homozygous for
ApoE Type 4 Allele
The following protocol is used to determine the effect of HMG-CoA reductase inhibitors on cerebrospinal fluid levels of ApoE in Alzheimer's patients homozygous for ApoE type 4 allele. Other HMG- CoA reductase inhibitors may be substituted for simvastatin.
A randomized, double-blind placebo controlled, parallel- design, multicenter six week study is conducted. Approximately 30 men and women (to provide 20 patients with baseline and follow-up lumbar punctures) between the ages of 50 and 85 years with a diagnosis of sporadic or late-onset familial AD, homozygous for the ApoE4 isoform, and with a low density lipoprotein (LDL) cholesterol level greater than 100 mg/dl are recruited for participation in the study and informed consent is obtained. (Patients incapable of giving informed consent have written consent from their guardian or representative.)
Patients qualifying for entry after screening are randomized to simvastatin, 40 mg/day or placebo for six weeks. A lumbar puncture will be performed prior to randomization and at Week 6 to determine cerebrospinal fluid levels of ApoE and other apolipoproteins. If the lumber puncture is judged traumatic (greater than grossly hemorrhage and greater than 50,000 RBC/mmβF), it is repeated in one week. Plasma is obtained at these time points for plasma total, LDL, HDL cholesterol and apolipoproteins including ApoE. For those patients in whom the six week lumbar puncture follow-up cannot be performed on time, a two week window is allowed (Week 4 to 8 of active treatment). The primary endpoint is a comparison between simvastatin and placebo groups in the mean cerebrospinal ApoE levels.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the casual variations, adaptations, modifications, deletions, or additions of procedures and protocols described herein, as come within the scope of the following claims and its equivalents.
Claims
1. A method for preventing, treating, or ameliorating the symptoms of Alzheimer's disease in a human patient comprising administration to the patient of an HMG-CoA reductase inhibitor.
2. The method for preventing, treating, or ameliorating the symptoms of Alzheimer's disease in a human patient of Claim 1 comprising administration to the patient of an HMG-CoA reductase inhibitor of structural formula (I),
(I)
wherein:
Z is selected from:
R is Cl-lθalkyl,
R2 is selected from:
(a) hydrogen,
(b) Cl-3 alkyl,
(c) hydroxy, and
(d) Cl-3 alkyl substituted with hydroxy; R3 is selected from:
(a) Cl-3 alkyl,
(b) hydroxy,
(c) oxo, and
(d) Cl-3 alkyl substituted with hydroxy; n is 0,1, or 2; a, b, c and d are all single bonds or a and c are double bonds or b and d are double bonds or one of a, b, c. or d is a double bond;
wherein X is NCH(CH3)2 or C(CH2)4.
wherein R4 and R are each independently selected from hydrogen, halogen, Cl-4 alkyl, Cl-4 alkoxy and trifluoromethyl, and
R5, R6, R75 and R^ are each independently selected from hydrogen, halogen, Cl-4 alkyl, and Cl-4 alkoxy; the corresponding open-ring dihydroxy acid forms thereof and pharmaceutically acceptable salts and esters thereof.
3. The method of Claim 1 wherein the HMG-CoA reductase inhibitor is selected from lovastatin, simvastatin, pravastatin and fluvastatin.
4. The method of Claim 3 wherein the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin.
5. The method of Claim 1 wherein the patient has at least one copy of the Apolipoprotein E type 4 allele.
6. The method of Claim 1 wherein the patient has Alzheimer's disease.
7. The method of Claim 1 wherein 1 to 1000 mg of the HMG-CoA reductase inhibitor is administered daily.
8. The method of Claim 7 wherein 5 to 100 mg of the HMG-CoA reductase inhibitor is administered daily.
9. The method of Claim 1 wherein the HMG-CoA reductase inhibitor is administered orally.
10. The method of Claim 7 wherein the HMG-CoA reductase inhibitor is administered by a controlled release dosage form.
11. The method of Claim 2 wherein the HMG-CoA reductase inhibitor is in the open ring dihydroxy acid form of formula (II):
(II) wherein R 10 is selected from: (a) hydrogen, (b) Cl-5alkyl,
(c) substituted Cl_5 alkyl in which the substituent is selected from the group consisting of:
(1) phenyl,
(2) dimethylamino, and
(3) acetylamino, and
(d) 2,3-dihydroxypropyl; and pharmaceutically acceptable salts thereof.
12. The method of Claim 2 wherein Z is:
(1) R3 is 5-OH, and a, b, c, and d are each single bonds, (2) R3 is 3-oxo and a and c are each double bonds, or c is a double bond, or
(3) R3 is 7-(l-hydroxyethyl), and b and d are double bonds; provided that when R2 is OH, b and d are double bonds or c is a double bond or a, b, c, and d are single bonds.
13. A method of lowering ApoE isoform 4 levels in the cerebrospinal fluid of a patient in need of such treatment comprising the administration to the patient of an HMG-CoA reductase inhibitor.
14. The method of lowering ApoE isoform 4 levels in the cerebrospinal fluid of the patient according to Claim 13 comprising administration to the patient of an HMG-CoA reductase inhibitor of structural formula (I),
(I)
wherein:
Z is selected from:
(a) hydrogen,
(b) Cl-3 alkyl,
(c) hydroxy, and (d) Cl-3 alkyl substituted with hydroxy; R3 is selected from:
(a) Cl-3 alkyl,
(b) hydroxy,
(c) oxo, and
(d) Cl-3 alkyl substituted with hydroxy; n is 0,1, or 2; a, b, c and d are all single bonds or a and c are double bonds or b and d are double bonds or one of a, b, (^ or d is a double bond;
wherein X is NCH(CH3)2 or C(CH2)4.
wherein R4 and R9 are each independently selected from hydrogen, halogen, Cl-4 alkyl, Cl-4 alkoxy and trifluoromethyl, and
R5, R6, R J_ and R8 are each independently selected from hydrogen, halogen, Cl_4 alkyl, and Cl-4 alkoxy; the corresponding open-ring dihydroxy acid forms thereof and pharmaceutically acceptable salts and esters thereof.
15. The method of Claim 13 wherein the HMG-CoA reductase inhibitor is selected from lovastatin, simvastatin, pravastatin and fluvastatin.
16. The method of Claim 15 wherein the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin.
17. The method of Claim 13 wherein the patient has at least one copy of the Apolipoprotein E type 4 allele.
18. The method of Claim 13 wherein the patient has Alzheimer's disease.
19. The method of Claim 13 wherein 1 to 1000 mg of the HMG-CoA reductase inhibitor is administered daily.
20. The method of Claim 19 wherein 5 to 100 mg of the HMG-CoA reductase inhibitor is administered daily.
21. The method of Claim 13 wherein the HMG-CoA reductase inhibitor is administered orally.
22. The method of Claim 13 wherein the HMG-CoA reductase inhibitor is administered by a controlled release dosage form.
23. The method of Claim 13 wherein the HMG-CoA reductase inhibitor is in the open ring dihydroxy acid form of formula (II):
CO wherein RlO is selected from: (a) hydrogen, (b) Cl-5alkyl,
(c) substituted C 1-5 alkyl in which the substituent is selected from the group consisting of:
(1) phenyl,
(2) dimethylamino, and
(3) acetylamino, and
(d) 2,3-dihydroxypropyl; and pharmaceutically acceptable salts thereof.
24. The method of Claim 2 wherein Z is:
(1) R3 is 5-OH, and a, b, c, and d are each single bonds, (2) R3 is 3-oxo and a and c are each double bonds, or c is a double bond, or
(3) R3 is 7-(l-hydroxyethyl), and b and d are double bonds; provided that when R2 is OH, b and d are double bonds or c is a double bond or a, b, c, and d are single bonds.
25. A method of lowering ApoE isoform 4 levels in a patient in need of such treatment comprising the administration to the patient of an HMG-CoA reductase inhibitor of structural formula (I),
(I)
wherein:
Z is selected from:
Rlis Ci-ioalkyl,
R2 is selected from:
(a) hydrogen,
(b) Cl-3 alkyl,
(c) hydroxy, and
(d) Cl-3 alkyl substituted with hydroxy; R3 is selected from:
(a) Cl-3 alkyl,
(b) hydroxy,
(c) oxo, and (d) Cl-3 alkyl substituted with hydroxy; n is 0,1, or 2; a, b, c and d are all single bonds or a and c are double bonds or b and d are double bonds or one of a, b, c or d is a double bond;
wherein X is NCH(CH3)2 or C(CH2)4.
wherein R4 and R are each independently selected from hydrogen, halogen, Cl-4 alkyl, Cl-4 alkoxy and trifluoromethyl, and R5, R6, R7? a d R^ are each independently selected from hydrogen, halogen, Cl-4 alkyl, and Cl-4 alkoxy; the corresponding open-ring dihydroxy acid forms thereof and pharmaceutically acceptable salts and esters thereof; provided that when Rl is 1 -methyl propyl or 1,1-dimethylpropyl, R^ is hydrogen and b and d represent double bonds, R2 is not methyl.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU73970/94A AU7397094A (en) | 1993-08-30 | 1994-07-05 | Prevention and treatment of alzheimer's disease |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11427093A | 1993-08-30 | 1993-08-30 | |
US11388093A | 1993-08-30 | 1993-08-30 | |
US113,880 | 1993-08-30 | ||
US114,270 | 1993-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995006470A1 true WO1995006470A1 (en) | 1995-03-09 |
Family
ID=26811581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/007518 WO1995006470A1 (en) | 1993-08-30 | 1994-07-05 | Prevention and treatment of alzheimer's disease |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7397094A (en) |
WO (1) | WO1995006470A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998047518A1 (en) * | 1997-04-17 | 1998-10-29 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Use of cholesterol-lowering agents to influence signal transduction processes in the cell membrane and in the prophylaxis or treatment of prion-associated diseases or alzheimer's disease |
WO1999015159A2 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
WO1999038498A1 (en) * | 1998-01-28 | 1999-08-05 | Warner-Lambert Company | Method for treating alzheimer's disease |
US5955472A (en) * | 1995-11-02 | 1999-09-21 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
WO1999048488A2 (en) * | 1998-03-23 | 1999-09-30 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
US6017913A (en) * | 1999-05-03 | 2000-01-25 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
US6046381A (en) * | 1998-04-30 | 2000-04-04 | The Regents Of The University Of California | Apolipoprotein E transgenic mice and assay methods |
WO2000028981A2 (en) * | 1998-11-13 | 2000-05-25 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
WO2001032161A2 (en) * | 1999-11-04 | 2001-05-10 | Andrx Corporation | Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
WO2001045698A1 (en) * | 1999-12-21 | 2001-06-28 | Merck & Co. Inc. | Combination therapy for treating neurodegenerative disease |
WO2002085368A2 (en) * | 2001-04-20 | 2002-10-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
EP1366061A2 (en) * | 2001-02-05 | 2003-12-03 | Andrx Corporation | Method of treating amyloid $g(b) precursor disorder |
EP1370210A2 (en) * | 2001-02-07 | 2003-12-17 | The McLean Hospital Corporation | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
WO2004006935A1 (en) * | 2002-07-11 | 2004-01-22 | Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung | Use of compounds that activate the sterol regulatory element binding protein (srebp) pathway |
EP1584333A2 (en) * | 1998-01-28 | 2005-10-12 | Warner-Lambert Company LLC | Use of acetylcoenzime A inhibitors for treating Alzheimer's disease |
EP1603548A2 (en) * | 2003-02-05 | 2005-12-14 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
WO2005120496A2 (en) * | 2004-05-24 | 2005-12-22 | Regents Of The University Of California | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE |
WO2005123068A2 (en) * | 2004-06-08 | 2005-12-29 | Axonyx, Inc. | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |
US7049058B2 (en) | 1997-11-25 | 2006-05-23 | Musc Foundation For Research Development | Methods for suppressing the induction of nitric oxide synthase in a cell |
US7064130B2 (en) | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
WO2007098417A2 (en) * | 2006-02-21 | 2007-08-30 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
US7964598B2 (en) | 1995-10-17 | 2011-06-21 | The J. David Gladstone Institutes | ApoE4 domain interaction inhibitors and methods of use thereof |
US8211922B2 (en) | 2005-07-11 | 2012-07-03 | Cortria Corporation | 1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities |
US8679534B2 (en) | 1997-12-12 | 2014-03-25 | Andrx Labs, Llc | HMG-CoA reductase inhibitor extended release formulation |
CN104188940A (en) * | 2014-09-26 | 2014-12-10 | 天津市聚星康华医药科技有限公司 | Simvastatin oral instant film and preparation method thereof |
-
1994
- 1994-07-05 AU AU73970/94A patent/AU7397094A/en not_active Abandoned
- 1994-07-05 WO PCT/US1994/007518 patent/WO1995006470A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, Volume 96, No. 23, issued 1982, TOBERT et al., "Cholesterol-Lowering Effect of Mevinolin, an Inhibitor of 3-Hydroxy-Methylglutaryl-Coenzyme A Reductase, in Healthy Volunteers", Abstract No. 193161s; & J. CLIN. INVEST., 69(4), 913-19. * |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964598B2 (en) | 1995-10-17 | 2011-06-21 | The J. David Gladstone Institutes | ApoE4 domain interaction inhibitors and methods of use thereof |
US5955472A (en) * | 1995-11-02 | 1999-09-21 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
WO1998047518A1 (en) * | 1997-04-17 | 1998-10-29 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Use of cholesterol-lowering agents to influence signal transduction processes in the cell membrane and in the prophylaxis or treatment of prion-associated diseases or alzheimer's disease |
US6274603B1 (en) | 1997-09-24 | 2001-08-14 | Mcgill University | Methods for increasing ApoE levels for the treatment of neurodegenerative disease |
WO1999015159A2 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
WO1999015159A3 (en) * | 1997-09-24 | 2000-02-17 | Nova Molecular Inc | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
JP2001517617A (en) * | 1997-09-24 | 2001-10-09 | ノヴァ モレキュラー インク. | Methods for increasing APOE levels for the treatment of neurodegenerative diseases |
US7396659B2 (en) | 1997-11-25 | 2008-07-08 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase to treat type 1 diabetes |
US8507219B2 (en) | 1997-11-25 | 2013-08-13 | Musc Foundation For Research Development | Method of treating inflammation with statins |
US7049058B2 (en) | 1997-11-25 | 2006-05-23 | Musc Foundation For Research Development | Methods for suppressing the induction of nitric oxide synthase in a cell |
US8679534B2 (en) | 1997-12-12 | 2014-03-25 | Andrx Labs, Llc | HMG-CoA reductase inhibitor extended release formulation |
AU762124B2 (en) * | 1998-01-28 | 2003-06-19 | Warner-Lambert Company | Method for treating Alzheimer's disease |
WO1999038498A1 (en) * | 1998-01-28 | 1999-08-05 | Warner-Lambert Company | Method for treating alzheimer's disease |
EP1584333A2 (en) * | 1998-01-28 | 2005-10-12 | Warner-Lambert Company LLC | Use of acetylcoenzime A inhibitors for treating Alzheimer's disease |
EP1584333A3 (en) * | 1998-01-28 | 2009-04-29 | Warner-Lambert Company LLC | Use of acetylcoenzime A inhibitors for treating Alzheimer's disease |
JP2010047616A (en) * | 1998-03-23 | 2010-03-04 | Childrens Medical Center Corp | Method for decreasing beta-amyloid protein |
JP2002507564A (en) * | 1998-03-23 | 2002-03-12 | チルドレンズ メディカル センター コーポレーション | Methods for reducing beta amyloid protein |
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
US6440387B1 (en) | 1998-03-23 | 2002-08-27 | Children's Medical Center Corporation | Methods for determining risk of Alzheimer's disease |
WO1999048488A2 (en) * | 1998-03-23 | 1999-09-30 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
WO1999048488A3 (en) * | 1998-03-23 | 2000-06-22 | Childrens Medical Center | Methods for decreasing beta amyloid protein |
US6046381A (en) * | 1998-04-30 | 2000-04-04 | The Regents Of The University Of California | Apolipoprotein E transgenic mice and assay methods |
WO2000028981A2 (en) * | 1998-11-13 | 2000-05-25 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
US6472421B1 (en) | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
JP2002529500A (en) * | 1998-11-13 | 2002-09-10 | ナイモックス コーポレーション | Methods for treating, preventing and reducing the risk of developing Alzheimer's disease using HMGCoA reductase inhibitors |
WO2000028981A3 (en) * | 1998-11-13 | 2000-11-09 | Nymox Corp | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
AU771254B2 (en) * | 1998-11-13 | 2004-03-18 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of Alzheimer's disease using an HMG CoA reductase inhibitor |
US6017913A (en) * | 1999-05-03 | 2000-01-25 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
WO2001032161A3 (en) * | 1999-11-04 | 2002-03-14 | Andrx Corp | Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
WO2001032161A2 (en) * | 1999-11-04 | 2001-05-10 | Andrx Corporation | Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
WO2001045698A1 (en) * | 1999-12-21 | 2001-06-28 | Merck & Co. Inc. | Combination therapy for treating neurodegenerative disease |
EP1366061A2 (en) * | 2001-02-05 | 2003-12-03 | Andrx Corporation | Method of treating amyloid $g(b) precursor disorder |
EP1366061A4 (en) * | 2001-02-05 | 2006-04-26 | Andrx Corp | Method of treating amyloid beta precursor disorders |
EP1370210A2 (en) * | 2001-02-07 | 2003-12-17 | The McLean Hospital Corporation | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
EP1370210A4 (en) * | 2001-02-07 | 2004-08-18 | Mclean Hospital Corp | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
US7064130B2 (en) | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
WO2002085368A2 (en) * | 2001-04-20 | 2002-10-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
WO2002085368A3 (en) * | 2001-04-20 | 2003-02-20 | Boehringer Ingelheim Pharma | Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
WO2004006935A1 (en) * | 2002-07-11 | 2004-01-22 | Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung | Use of compounds that activate the sterol regulatory element binding protein (srebp) pathway |
EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | Method and composition for treating neurodegenerative disorders |
EP1603548A2 (en) * | 2003-02-05 | 2005-12-14 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
WO2005120496A2 (en) * | 2004-05-24 | 2005-12-22 | Regents Of The University Of California | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE |
WO2005120496A3 (en) * | 2004-05-24 | 2006-10-12 | Univ California | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE |
US8222293B2 (en) * | 2004-05-24 | 2012-07-17 | Regents of the University of Carolina | Treating learning deficits with inhibitors of Hmg CoA reductase |
WO2005123068A3 (en) * | 2004-06-08 | 2006-08-17 | Axonyx Inc | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |
WO2005123068A2 (en) * | 2004-06-08 | 2005-12-29 | Axonyx, Inc. | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |
US8211922B2 (en) | 2005-07-11 | 2012-07-03 | Cortria Corporation | 1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities |
US8481570B2 (en) | 2005-07-11 | 2013-07-09 | Cortria Corporation | 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities |
WO2007098417A3 (en) * | 2006-02-21 | 2007-10-18 | Oklahoma Med Res Found | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
WO2007098417A2 (en) * | 2006-02-21 | 2007-08-30 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
CN104188940A (en) * | 2014-09-26 | 2014-12-10 | 天津市聚星康华医药科技有限公司 | Simvastatin oral instant film and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
AU7397094A (en) | 1995-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995006470A1 (en) | Prevention and treatment of alzheimer's disease | |
Tobert | New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. | |
AU2003227516B2 (en) | A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
AU680864B2 (en) | Combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorption inhibitor | |
Yamamoto et al. | Therapeutic effects of ML-236B in primary hypercholesterolemia | |
US20060004076A1 (en) | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | |
EP1534298A2 (en) | Novel anticholesterol compositions and method for using same | |
Illingworth et al. | Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia | |
Abedin et al. | Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs | |
Saunders et al. | Lovastatin and gallstone dissolution: a preliminary study | |
US4355027A (en) | Process and composition for treating disorders by administering piracetam and choline | |
JPH0623105B2 (en) | Pharmaceutical composition for the treatment of epileptic seizures | |
US4153700A (en) | Treatment of the acute after-effects resulting from alcohol ingestion | |
CA2426492C (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
Chin-Dusting et al. | Lipids and atherosclerosis: clinical management of hypercholesterolaemia | |
Duvall et al. | Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy | |
JPH04502020A (en) | Orally administered porphyrins to control intestinal iron absorption | |
JPH05504971A (en) | Pharmaceutical composition for lowering lipids containing bambuterol | |
Hayashi et al. | Preventative and therapeutic effects of AE0047 on renal injury in stroke‐prone spontaneously hypertensive rats | |
EP0116238A1 (en) | Therapeutic compositions and their use in enhancing brain function | |
JPH07233062A (en) | Composition for treating skin pruritus of patient requiring artificial dialysis and composition for treating hyperparathyroidism | |
US20050107465A1 (en) | Composition for treating inflammatory bowel disease | |
Nakashima | Treatment of hyperlipidemia | |
Tikkanen | 2 Practical drug therapy for common hyperlipidaemias | |
CA2558708A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR BY CA CN CZ FI GE HU JP KE KG KR KZ LK LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US US UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |